The significance of the study:
Given that: (1) 15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD; and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.
Research findings to Therapeutic opportunity:
This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD).
Lactobacillus fermentum DR9 (LF-DR9), by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Lactobacillus fermentum DR9 (LF-DR9), either alone or in combination with other drugs, may be used to treat NAFLD.
Figure 1. Mechanistic insights into how Lactobacillus fermentum DR9 (LF-DR9) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.
Figure 2. Lactobacillus fermentum DR9 (LF-DR9) functions as a cholesterol-lowering agent. Lactobacillus fermentum DR9 (LF-DR9) lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR
[easy_payment currency=”USD”]
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Lactobacillus fermentum DR9 (LF-DR9) decrease the expression of HMGCR and prevent NAFLD?
Amount: $750#
# Research cooperation
For purchase and payment details, you may reach us at info@genomediscovery.org
References:
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus fermentum DR9 (LF-DR9) decreases the levels of HMGCR, triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 17/December/2018, 11.55 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org
Courtesy: When you cite, drop us a line at info@genomediscovery.org